Arvinas Operations, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 218
Rang # Quantité totale PI 5 920
Note d'activité PI 3,2/5.0    256
Rang # Activité PI 2 773
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

88 27
27 9
60 2
5
 
Dernier brevet 2025 - Brm targeting compounds and asso...
Premier brevet 2015 - Imide-based modulators of proteo...
Dernière marque 2025 - Govepanu
Première marque 2014 - ARVINAS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations for the treatment of cancer
2024 P/S Pharmaceutical preparations for the treatment of cancer.
P/S Pharmaceutical preparations for the treatment of cancer.
Invention Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor. ...
P/S Pharmaceutical preparations for the treatment of cancer. Medical informational services, includin...
Invention Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer. The invention relates to a met...
Invention Dgk targeting compounds and uses thereof. e.ge.g., cancer) and viral infections.
Invention Hpk1 targeting compounds and uses thereof. Described herein are compounds that modulate hematopoi...
Invention Compounds useful in the treatment of kras mediated disorders. e.g.e.g., compounds of Formula (I))...
Invention Compounds and methods for the targeted degradation of androgen receptor. The present disclosure ...
Invention Compounds and methods for the targeted degradation of androgen receptor. This disclosure pertain...
Invention Compounds and methods for the targeted degradation of androgen receptor. This disclosure pertains...
P/S Pharmaceutical preparations for the treatment of cancer
Invention Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer. Disc...
Invention Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, a...
Invention Solid oral dosage forms of estrogen receptor degraders. Disclosed herein are solid oral dosage fo...
Invention Combinations of estrogen receptor degraders and akt inhibitors. Disclosed herein are methods for ...
Invention Indazole based compounds and associated methods of use. Bifunctional compounds, which find utili...
Invention Bavdegalutamide for treating prostate cancer without ar l702h mutation. This disclosure pertains ...
Invention Use of an androgen receptor degrader protac for the treatment of prostate cancer. The present app...
Invention Egfr proteolysis targeting chimeric molecules and associated methods of use. The present inventi...
Invention Crystalline forms of a compound for the targeted degradation of the androgen receptor. The prese...
Invention Crystalline forms of a compound for the targeted degradation of the androgen receptor. The presen...
Invention Dosage regimens of estrogen receptor degraders. Disclosed herein are methods for treating cancer ...
Invention Modulators of bcl6 proteolysis and associated methods of use. Bifunctional compounds, which find...
Invention Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor. Disclosed h...
Invention Cereblon-based kras degrading protacs and uses related thereto. Provided herein are compounds th...
Invention Cereblon-based kras degrading protacs ans uses related thereto. Provided herein are compounds tha...
Invention Pharmaceutical formulations of an androgen receptor-targeting protein degrader. The present discl...
Invention Modulators of bcl6 proteolysis and associated methods of use. This application pertains to the u...
Invention Modulators of bcl6 proteolysis and associated methods of use. This application pertains to the us...
2023 Invention Method of treating breast cancer. The invention relates to a method for treating cancer in a subj...
Invention Casitas b-lineage lymphoma protooncogene b (cbl-b) degrading compounds and associated methods of ...
Invention Selective modulators of mutant lrrk2 proteolysis and associated methods of use. Bifunctional com...
Invention Rapid accelerated fibrosarcoma (raf) degrading compounds and associated methods of use. or pharm...
Invention Modulators of bcl6 proteolysis and associated methods of use. This disclosure pertains to bifunc...
Invention Modulators of bcl6 proteolysis and associated methods of use. This disclosure pertains to bifunct...
Invention Methods of treating prostate cancer. The present application relates to treating and/or preventi...
Invention Tau-protein targeting compounds and associated methods of use. The present disclosure relates to...
Invention Modulators of alpha-synuclein proteolysis and associated methods of use. The present disclosure ...
Invention Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use. or pha...
Invention Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use. Provide...
Invention Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use. The prese...
Invention Vepdegestrant for use in treating cancer. Disclosed herein are methods for treating cancer compri...
Invention Imide-based modulators of proteolysis and associated methods of use. The description relates to ...
Invention Modulators of tyk2 proteolysis and associated methods of use. Bifunctional compounds, which find ...
2022 Invention Compounds and methods for the targeted degradation of the androgen receptor. The present inventi...
Invention Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders. The...
Invention Brm targeting compounds and associated methods of use. The present disclosure relates to bifunct...
Invention Brm degrading compounds and associated methods of use. The present disclosure relates to bifunct...
P/S Pharmaceutical preparations for use in treating oncology, immunology, and inflammatory diseases, ...
P/S Pharmaceutical preparations for use in treating oncology, immunology, and inflammatory diseases,...
2021 P/S Agricultural products development
P/S Bi-functional small molecules that mediate targeted protein degradation through the ubiquitin pro...
2020 P/S Pharmaceutical products development of new small molecules aimed at degrading disease-causing cel...
2018 P/S Pharmaceutical preparations comprising small molecules for degrading disease-causing cellular pro...